ResearchPublished All news from that day
Anthropic reports early Claude drug-development results with six partners; none of the drugs is yet in human trials
Partners used Claude and Claude Code on antibody design, lab data and documentation review, Anthropic says.
Check our sources · 13 facts from 1 sourceAnthropic published on 27 October 2026 the results of research partnerships with six organizations developing new medicines.
At Generate Biomedicines, six scientists used Claude Code to propose new designs for part of a CAR T-cell therapy; one design was about 70% shorter than the standard version and allowed immune cells to make roughly 10 times as many receptors.
Divergence Labs, which works on food allergies, had Claude generate roughly 35,000 antibody designs in about a month; early tests found three designs that could bind to IgE and 20 that could dislodge it, and three of those 20 appeared to dislodge IgE more than the standard medication.
At BigHat Biosciences, Claude connected to the lab's data system proposed changes to two antibody fragments; the lab made and tested about 1,010 variants in about 10 weeks, and the best versions bound more than 10 times more tightly.
At Enveda, on 1,061 pages of documentation, Claude caught all 11 issues human reviewers had spotted and flagged seven they had missed, and human review time fell 89%, from over 25 hours to less than three.
Anthropic also says it acquired Mithril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy, and expects a drug to be ready to start clinical trials in humans as soon as late 2028.
Anthropic says the work is mostly preclinical and is not yet at the stage where drugs are being tested in humans. All results come from Anthropic's own post.
Underlined sentences link to the facts we checked. Dotted words open a short explainer.
Fact 8 of 13 · from Anthropic, 27 Oct 2026
Over tests on 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted—and flagged seven they’d missed.
Fact 12 of 13 · from Anthropic, 27 Oct 2026
so far it is mostly preclinical— that is, for the most part, it isn’t yet at the stage where the drugs are being tested in humans.
Your reaction
We count reactions per story and day, never who reacted. The counts help us choose what goes in the monthly issue. If you are signed in, your own page shows yours too.
We count reactions per story and day, never who reacted. They help choose what goes in the monthly issue.
Check our sources
Every sentence above is checked against this source.
1 Early progress on accelerating drug development with Claude
Open the source archived copy-
Anthropic's post "Early progress on accelerating drug development with Claude" is dated Oct 27, 2026 and describes "deep research partnerships with six organizations developing new medicines".
citePublished Oct 27, 2026 ... our scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences , Bristol Myers Squibb , Divergence Labs , Enveda , Generate Biomedicines , and The Column Group .
-
Anthropic says "Six Generate scientists used Claude Code to propose new designs for this part." (Generate Biomedicines, a CAR T-cell therapy)
citeSix Generate scientists used Claude Code to propose new designs for this part.
-
Anthropic says "One design was about 70% shorter than the standard version" and "it allowed immune cells to make roughly 10 times as many receptors"; the results are reported by Anthropic and its partner. the company says
citeOne design was about 70% shorter than the standard version, and in lab tests it was more effective: it allowed immune cells to make roughly 10 times as many receptors
-
Anthropic says Divergence Labs' work "generated roughly 35,000 antibody designs in about a month".
citegenerated roughly 35,000 antibody designs in about a month to be narrowed down and tested.
-
Anthropic says early tests found "three designs that could bind to IgE, and 20 that could dislodge it. Three of those 20 appeared to dislodge IgE more than the standard medication."
citethree designs that could bind to IgE, and 20 that could dislodge it. Three of those 20 appeared to dislodge IgE more than the standard medication.
-
Anthropic says "Claude, connected to BigHat's lab data system, Reccy, proposed changes to each molecule", and the lab "made and tested about 1,010 variants in about 10 weeks".
citeClaude, connected to BigHat’s lab data system, Reccy, proposed changes to each molecule, and BigHat’s lab made and tested about 1,010 variants in about 10 weeks.
-
Anthropic says at BigHat "the best versions bound more than 10x more tightly", "the cancer-targeting lead stayed in solution 18°C higher" and "the lead for longer-lasting drugs clumped more than 100x more slowly."
citethe best versions bound more than 10x more tightly, the cancer-targeting lead stayed in solution 18°C higher, and the lead for longer-lasting drugs clumped more than 100x more slowly.
-
Anthropic says that at Enveda, "Over tests on 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted—and flagged seven they'd missed."
citeOver tests on 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted—and flagged seven they’d missed.
-
Anthropic says Enveda's method "reduced human review time by 89%, from over 25 hours to less than three."
citethis method reduced human review time by 89%, from over 25 hours to less than three.
-
Anthropic says "We've acquired Mithril Medicine", "a one-person company that has been developing treatments for two rare forms of muscular dystrophy."
citeWe’ve acquired Mithril Medicine, a one-person company that has been developing treatments for two rare forms of muscular dystrophy.
-
Anthropic says "we expect a drug to be ready to start clinical trials in humans as soon as late 2028" (a stated expectation, not a result).
citeIf his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028.
-
Anthropic says the work is mostly preclinical and "it isn't yet at the stage where the drugs are being tested in humans."
citeso far it is mostly preclinical— that is, for the most part, it isn’t yet at the stage where the drugs are being tested in humans.
-
Anthropic's page names Claude Code (in the Generate Biomedicines section) and Claude generally as the AI used, and names no other model.
citeSix Generate scientists used Claude Code to propose new designs for this part.
Every sentence above is checked against this source. Each fact has its own address you can cite.
Source 1 · Anthropic · 27 Oct 2026
Early progress on accelerating drug development with Claude
Anthropic's post "Early progress on accelerating drug development with Claude" is dated Oct 27, 2026 and describes "deep research partnerships with six organizations developing new medicines".
Published Oct 27, 2026 ... our scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences , Bristol Myers Squibb , Divergence Labs , Enveda , Generate Biomedicines , and The Column Group .
Anthropic says "Six Generate scientists used Claude Code to propose new designs for this part." (Generate Biomedicines, a CAR T-cell therapy)
Six Generate scientists used Claude Code to propose new designs for this part.
Anthropic says "One design was about 70% shorter than the standard version" and "it allowed immune cells to make roughly 10 times as many receptors"; the results are reported by Anthropic and its partner. the company says
One design was about 70% shorter than the standard version, and in lab tests it was more effective: it allowed immune cells to make roughly 10 times as many receptors
Show all 13 factsShow fewer facts
Anthropic says Divergence Labs' work "generated roughly 35,000 antibody designs in about a month".
generated roughly 35,000 antibody designs in about a month to be narrowed down and tested.
Anthropic says early tests found "three designs that could bind to IgE, and 20 that could dislodge it. Three of those 20 appeared to dislodge IgE more than the standard medication."
three designs that could bind to IgE, and 20 that could dislodge it. Three of those 20 appeared to dislodge IgE more than the standard medication.
Anthropic says "Claude, connected to BigHat's lab data system, Reccy, proposed changes to each molecule", and the lab "made and tested about 1,010 variants in about 10 weeks".
Claude, connected to BigHat’s lab data system, Reccy, proposed changes to each molecule, and BigHat’s lab made and tested about 1,010 variants in about 10 weeks.
Anthropic says at BigHat "the best versions bound more than 10x more tightly", "the cancer-targeting lead stayed in solution 18°C higher" and "the lead for longer-lasting drugs clumped more than 100x more slowly."
the best versions bound more than 10x more tightly, the cancer-targeting lead stayed in solution 18°C higher, and the lead for longer-lasting drugs clumped more than 100x more slowly.
Anthropic says that at Enveda, "Over tests on 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted—and flagged seven they'd missed."
Over tests on 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted—and flagged seven they’d missed.
Anthropic says Enveda's method "reduced human review time by 89%, from over 25 hours to less than three."
this method reduced human review time by 89%, from over 25 hours to less than three.
Anthropic says "We've acquired Mithril Medicine", "a one-person company that has been developing treatments for two rare forms of muscular dystrophy."
We’ve acquired Mithril Medicine, a one-person company that has been developing treatments for two rare forms of muscular dystrophy.
Anthropic says "we expect a drug to be ready to start clinical trials in humans as soon as late 2028" (a stated expectation, not a result).
If his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028.
Anthropic says the work is mostly preclinical and "it isn't yet at the stage where the drugs are being tested in humans."
so far it is mostly preclinical— that is, for the most part, it isn’t yet at the stage where the drugs are being tested in humans.
Anthropic's page names Claude Code (in the Generate Biomedicines section) and Claude generally as the AI used, and names no other model.
Six Generate scientists used Claude Code to propose new designs for this part.
Topics
The morning email
On the mornings we publish: the three top stories and up to four short ones. Free.
We email you a link to confirm. An issue may include one sponsor, always labelled Sponsored · Advertisement. Our emails count opens and clicks, not who made them. Unsubscribe in one click. What we keep